Published in Cancer on November 01, 2005
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefes Arch Clin Exp Ophthalmol (2012) 1.42
The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta (2011) 1.36
The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD. Mol Biol Cell (2007) 1.33
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag (2006) 1.20
Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J (2015) 1.03
PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. Br J Cancer (2009) 0.94
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget (2014) 0.90
The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 0.87
Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. J Clin Endocrinol Metab (2011) 0.87
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. J Exp Clin Cancer Res (2014) 0.87
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res (2008) 0.86
SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma. Mikrochim Acta (2011) 0.85
Analysis of a mathematical model of apoptosis: individual differences and malfunction in programmed cell death. J Clin Monit Comput (2013) 0.85
Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci (2009) 0.84
Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. Biomed Res Int (2014) 0.84
The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. Coord Chem Rev (2009) 0.84
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. Onco Targets Ther (2009) 0.83
BU-32: a novel proteasome inhibitor for breast cancer. Breast Cancer Res (2009) 0.83
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs (2014) 0.79
Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells. Br J Cancer (2011) 0.79
Flipping the switch from g1 to s phase with e3 ubiquitin ligases. Genes Cancer (2012) 0.78
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells. Mol Cell Biochem (2013) 0.78
Siah1 proteins enhance radiosensitivity of human breast cancer cells. BMC Cancer (2010) 0.78
Proteomic profile of pre - B2 lymphoblasts from children with acute lymphoblastic leukemia (ALL) in relation with the translocation (12; 21). Clin Proteomics (2014) 0.77
Bortezomib treatment causes long-term testicular dysfunction in young male mice. Mol Cancer (2014) 0.75
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome. Springerplus (2013) 0.75
Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation. Bone Marrow Res (2012) 0.75
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. Cancer Sci (2017) 0.75
Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors. Cancer Sci (2014) 0.75
Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line. Chin J Cancer Res (2011) 0.75
The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy. PLoS One (2016) 0.75
Novel Strategies to Improve the Endocrine Therapy of Breast Cancer. Oncol Rev (2017) 0.75
Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature. Mol Clin Oncol (2017) 0.75
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med (2003) 7.35
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Cell death independent of caspases: a review. Clin Cancer Res (2005) 3.85
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol (2010) 2.75
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol (2009) 2.49
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res (2003) 2.44
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica (2007) 2.03
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res (2006) 1.99
Apoptosis: target of cancer therapy. Clin Cancer Res (2002) 1.99
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood (2002) 1.87
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol (2012) 1.85
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol (2013) 1.80
Changing patient perceptions of the side effects of cancer chemotherapy. Cancer (2002) 1.78
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med (2003) 1.72
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol (2009) 1.69
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer (2006) 1.67
Thalidomide for treatment of multiple myeloma: 10 years later. Blood (2008) 1.66
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol (2012) 1.60
Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol (2007) 1.60
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood (2010) 1.56
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol (2008) 1.52
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood (2010) 1.51
EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol (2007) 1.48
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol (2009) 1.45
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A (2010) 1.45
Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol (2008) 1.44
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res (2002) 1.44
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica (2010) 1.42
How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging (2006) 1.41
Quality trials and quality of life in non-small-cell lung cancer. J Clin Oncol (2003) 1.41
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer (2007) 1.38
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res (2012) 1.38
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol (2008) 1.37
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther (2007) 1.34
Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res (2004) 1.34
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer (2006) 1.33